SCHEMBL574473

SCHEMBL574473

CC(N)(CCCCN)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ARG1 P05089 2/20 0.62
ARG2 P78540 2/20 0.62
GGT1 P19440 1/20 0.52
ODC1 P11926 2/20 0.45
BLM P54132 4/20 0.42
LMNA P02545 3/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.42
PMP22 Q01453 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CYP2D6 P10635 1/20 0.41
NFKB1 P19838 1/20 0.41
NPSR1 Q6W5P4 2/20 0.39
THRB P10828 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
PLG P00747 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL161423 1.00 ARG1 (0.62) ARG1ARG2GGT1ODC1BLM
SCHEMBL201390 1.00 ARG1 (0.62) ARG1ARG2GGT1ODC1BLM
SCHEMBL23733387 0.98 ARG1 (0.60) ARG1ARG2GGT1ODC1BLM
SCHEMBL5320545 0.98 ARG1 (0.60) ARG1ARG2GGT1ODC1BLM
SCHEMBL5325205 0.98 ARG1 (0.60) ARG1ARG2GGT1ODC1BLM
SCHEMBL162369 0.93 ARG1 (0.59) ARG1ARG2GGT1ODC1BLM
SCHEMBL162370 0.93 ARG1 (0.59) ARG1ARG2GGT1ODC1BLM
SCHEMBL574141 0.93 ARG1 (0.59) ARG1ARG2GGT1ODC1BLM
Hydrochloric Acid SCHEMBL3219766 0.91 ARG1 (0.57) ARG1ARG2GGT1ODC1BLM
Water SCHEMBL7726696 0.91 ARG1 (0.57) ARG1ARG2GGT1ODC1BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 553 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025109003-A1 P-CADHERIN LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2025-05-30 WO claimed
EP-4482578-A1 CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY Corteria Pharmaceuticals (FR) 2025-01-01 EP claimed
CN-118843638-A CRF2 receptor agonists and their use in therapy 科尔特瑞制药公司 2024-10-25 CN claimed
CN-116804046-B Cyclic cation antibacterial peptide and application thereof 科睿铂泰医药科技(深圳)有限责任公司 2024-07-16 CN claimed
EP-4392440-A2 COMBINATION OF RELAXIN AND VASOPRESSIN ANALOGUES FOR TREATMENT OF RENAL DISORDERS OR CONDITIONS River 2 Renal Corp. (US) 2024-07-03 EP claimed
CN-116804046-A Cyclic cation antibacterial peptide and application thereof 科睿铂泰医药科技(深圳)有限责任公司 2023-09-26 CN claimed
EP-4237427-A1 ANTIBACTERIAL CYCLOPEPTIDES TARGETING ACINETOBACTER AND OTHER GRAM-NEGATIVE PATHOGENS University of Utah Research Foundation (US) 2023-09-06 EP claimed
WO-2023161229-A1 CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY CORTERIA PHARMACEUTICALS (FR) 2023-08-31 WO claimed
EP-4234574-A1 CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY Corteria Pharmaceuticals (FR) 2023-08-30 EP claimed
CN-116670151-A Antibacterial cyclic peptides targeting acinetobacter and other gram negative pathogens 犹他大学研究基金会 2023-08-29 CN claimed
WO-2015084921-A1 CLEANING FORMULATION FOR REMOVING RESIDUES ON SURFACES FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) 2015-06-11 WO claimed
US-20150159124-A1 CLEANING FORMULATION FOR REMOVING RESIDUES ON SURFACES FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. 2015-06-11 US claimed
WO-2015060954-A1 CLEANING FORMULATIONS FOR REMOVING RESIDUES ON SURFACES FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) 2015-04-30 WO claimed
US-20150111804-A1 CLEANING FORMULATIONS FOR REMOVING RESIDUES ON SURFACES FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. 2015-04-23 US claimed
US-20120121591-A1 SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3 AMGEN INC. (US) 2012-05-17 US claimed
EP-2432488-A2 SELECTIVE AND POTENT PEPTIDE INHIBITORS OF KV1.3 Amgen, Inc (US) 2012-03-28 EP claimed
WO-2010108154-A2 SELECTIVE AND POTENT PEPTIDE INHIBITORS OF KV1.3 AMGEN INC. (US) 2010-09-23 WO claimed
WO-2008077194-A1 RECEPTOR AGONISTS XENOME LTD (AU) 2008-07-03 WO claimed
WO-2006052637-A1 RETROCYCLINS: ANTIVIRAL AND ANTIMICROBIAL PEPTIDES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-05-18 WO claimed
US-4066501-A CORYNEBACTERIA, BREVIBACTERIA AJINOMOTO CO., INC. (JA) 1978-01-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120121591-A1 SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3 KCNJ4, KCNK4, KCNQ4 ARG1 2721/4885ARG2 2689/4885GGT1 4560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.